About the Company
Tradipitant (VLY-686 or LY686017) is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Vanda Pharmaceuticals is a U.S. pharmaceutical company that as of November 2015 only has three drugs in their product pipeline: tasimelteon, VLY-686, and iloperidone.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VNDA News
Vanda Pharmaceuticals (NASDAQ: VNDA)
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis ...
Supreme Court will not hear D.C. biotech's patent infringement appeal
Future drug sales at one D.C. biotech stand to decline after the Supreme Court rejected its request to review its patent ...
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Vanda is expected to post earnings of $0.05 per share for the current quarter, representing a year-over-year change of -16.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
D.C. biotech adopts poison pill after rejecting acquisition offer
A D.C. biotech has adopted a shareholder rights plan, better known as a poison pill, after rejecting an unsolicited ...
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) confirmed that, since March 2024, it had received several unsolicited proposals from ...
Vanda Pharmaceuticals gets grant for use of melatonin agonist tasimelteon in treating circadian rhythms
Discover how Vanda Pharmaceuticals' patent revolutionizes circadian rhythm disorder treatment with tasimelteon, tailored to patients' beta-adrenergic receptor antagonist use.
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not ...
Vanda Pharmaceuticals gets grant for treatment of circadian rhythm disorder using tasimelteon
Discover how Vanda Pharmaceuticals' patent for using tasimelteon to treat circadian rhythm disorders, including in blind patients, is revolutionizing sleep-wake patterns and improving quality of life.
Vanda Pharmaceuticals Inc VNDA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Vanda Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...